Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads

It was a good day for biotech venture news, as early-stage investor Third Rock closed its second fund and Relypsa reported a massive $70 million Series B funding to push its potassium binding agent into pivotal trials.